Arrowhead Pharmaceuticals, Inc.
ARWR · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 28.34 | -0.02 | -0.98 | -0.87 |
| FCF Yield | 3.40% | -26.05% | -11.47% | -5.42% |
| EV / EBITDA | 47.14 | -4.86 | -17.97 | -21.31 |
| Quality | ||||
| ROIC | -0.68% | -57.37% | -30.98% | -31.05% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 5.96 | 0.76 | 0.74 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 51.04% | -75.56% | 20.30% | 40.34% |
| Free Cash Flow Growth | 125.96% | -82.78% | -75.02% | -227.94% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | -0.73 | -1.55 | 0.16 |
| Interest Coverage | -1.10 | -18.58 | -11.19 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 3.00 | 0.00 | 0.00 | 2.12 |